Title: The Hidden Dangers of CBD: A New FDA Study Reveals Potential Liver Harm
Introduction: The world has been abuzz with the popularity of cannabidiol (CBD) products in recent years. From capsules to gummies, edibles, oils and lotions, these products have become increasingly commonplace in the United States. However, a new clinical trial conducted by scientists from the Food and Drug Administration's Division of Applied Regulatory Science has raised concerns about the safety of even low doses of CBD. The study found that some people may experience liver damage or inflammation after using these products.
Historical Context: CBD is a compound derived from cannabis plants, and it does not produce a "high" like its cousin THC (tetrahydrocannabinol). It has been touted for its potential health benefits such as reducing anxiety, pain relief, and improving sleep. However, the FDA's recent study is not the first time concerns have been raised about CBD's safety. In 2019, the World Health Organization (WHO) warned that using CBD could potentially cause liver injury in some individuals.
Findings of the Study: The randomized double-blind placebo-controlled trial involved 201 healthy middle-aged men and women who received either a low dose of oral CBD or a placebo for four weeks. While most participants showed no adverse effects, approximately 5% experienced significantly elevated levels of the liver enzyme aminotransferase – an indicator of liver cell damage or inflammation. Women appeared to be more vulnerable than men, and their livers returned to normal within one or two weeks after stopping CBD use.
Potential Implications: The findings have significant implications for individuals using over-the-counter CBD supplements. Many users may not be aware of the potential risks associated with these products, assuming that they are entirely benign. This study highlights the need for further research into the long-term effects of CBD on human health and liver function. It also underscores the importance of proper regulation and labeling of CBD products to ensure consumer safety.
Conclusion: The FDA's recent clinical trial raises serious concerns about the potential dangers of using even low doses of cannabidiol (CBD). While most users may not experience any adverse effects, this study suggests that some individuals could face liver damage or inflammation after consuming CBD products. As more people turn to these supplements for their perceived health benefits, it is crucial that we continue to investigate the long-term impacts of CBD on human health and take steps towards ensuring consumer safety through proper regulation and labeling.
Source: [Original Article](https://www.nbcnews.com/health/health-news/cbd-liver-damage-study-potential-problems-rcna217186) #even
Check out my AI projects on <a href='https://huggingface.co/ghostail'>Hugging Face</a>, join our community on <a href='https://discord.com/invite/zgKZUJ6V8z'>Discord</a>, and explore my services at <a href='https://ghostai.pro'>GhostAI</a>!